Veterinary medicine and science · 2026
Effectiveness of Ginsenoside Rh2 Treatment in Mice Experimentally Infected With Cryptosporidium parvum.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yildirim Esengul, Balikci Engin
Аннотация
OBJECTIVE: To evaluate the therapeutic potential of Ginsenoside Rh2 in mice experimentally infected with Cryptosporidium parvum and to compare the efficacy of two Ginsenoside Rh2 dosing regimens.
ANIMALS: Fifty male BALB/c mice, aged four weeks, were used.
METHODS: Mice were immunosuppressed with dexamethasone and orally infected with 3 × 105 C. parvum oocysts. Animals were randomly assigned to five groups (n = 10): healthy control (HC), infected control (IC), halofuginone-treated (HAL), low-dose Ginsenoside Rh2 (GIN50) and high-dose Ginsenoside Rh2 (GIN100). Mice were treated for 5 days, and body weights and oocyst counts were recorded at several time points. On Day 18 (T18), mice were euthanized, and intestinal samples were collected for histopathology.
RESULTS: The HAL, GIN50 and GIN100 groups showed significant body-weight gains, with the GIN100 group exhibiting the greatest increase from T0 to T18 (16.70 ± 0.14 g to 24.00 ± 0.24 g, p < 0.001). Oocyst counts decreased significantly in all treated groups over time. In the GIN100 group, oocyst counts decreased from 3.69 ± 0.01 at T0 to 0.99 ± 0.03 at T5 (p < 0.001), and no oocysts were detected at T18. Group-level histopathological assessment showed the least lesion severity in the HAL group, whereas GIN50 and GIN100 showed comparable mild lesion scores.
CONCLUSION: Ginsenoside Rh2, particularly at 100 mg/kg, reduced C. parvum oocyst shedding and improved body-weight recovery in experimentally infected mice. However, its comparative efficacy, safety profile and mechanism of action require further investigation before it can be considered an established alternative treatment.
ANIMALS: Fifty male BALB/c mice, aged four weeks, were used.
METHODS: Mice were immunosuppressed with dexamethasone and orally infected with 3 × 105 C. parvum oocysts. Animals were randomly assigned to five groups (n = 10): healthy control (HC), infected control (IC), halofuginone-treated (HAL), low-dose Ginsenoside Rh2 (GIN50) and high-dose Ginsenoside Rh2 (GIN100). Mice were treated for 5 days, and body weights and oocyst counts were recorded at several time points. On Day 18 (T18), mice were euthanized, and intestinal samples were collected for histopathology.
RESULTS: The HAL, GIN50 and GIN100 groups showed significant body-weight gains, with the GIN100 group exhibiting the greatest increase from T0 to T18 (16.70 ± 0.14 g to 24.00 ± 0.24 g, p < 0.001). Oocyst counts decreased significantly in all treated groups over time. In the GIN100 group, oocyst counts decreased from 3.69 ± 0.01 at T0 to 0.99 ± 0.03 at T5 (p < 0.001), and no oocysts were detected at T18. Group-level histopathological assessment showed the least lesion severity in the HAL group, whereas GIN50 and GIN100 showed comparable mild lesion scores.
CONCLUSION: Ginsenoside Rh2, particularly at 100 mg/kg, reduced C. parvum oocyst shedding and improved body-weight recovery in experimentally infected mice. However, its comparative efficacy, safety profile and mechanism of action require further investigation before it can be considered an established alternative treatment.